CODOX-M/IVAC regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-do...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}}CODOX-M/IVAC Regimen; Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen; McGrath Regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[doxorubicin]] and high-dose [[methotrexate]] (CODOX-M) alternating with [[ifosfamide]], [[etoposide]] and high-dose [[cytarabine]] (IVAC), used as a treatment for aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment for AIDS-related and high-risk [[Burkitt's lymphoma]]. Intrathecal [[cytarabine]] and [[methotrexate]] are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement. | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[doxorubicin]] and high-dose [[methotrexate]] (CODOX-M) alternating with [[ifosfamide]], [[etoposide]] and high-dose [[cytarabine]] (IVAC), used as a treatment for aggressive forms of [[non-Hodgkin's lymphoma]]; also used as primary treatment for AIDS-related and high-risk [[Burkitt's lymphoma]]. Intrathecal [[cytarabine]] and [[methotrexate]] are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63448}}</ref> | ||
==Regimen== | |||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|V|Vincristine}} | {{chemo|V|Vincristine}} | ||
{{chemo|DOX|Doxorubicin}} | {{chemo|DOX|Doxorubicin}} | ||
{{chemo|M|Methotrexate}} | {{chemo|M|Methotrexate}} | ||
{{chemo|I|Ifosfamide}} | {{chemo|I|Ifosfamide}} | ||
{{chemo| | {{chemo|V|Vepesid (etoposide)}} | ||
{{chemo|C | {{chemo|AC|Ara-C (cytarabine)}} | ||
==Indications== | ==Indications== | ||
*AIDS-related and high-risk [[Burkitt's lymphoma]] | *AIDS-related and high-risk [[Burkitt's lymphoma]]<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63448}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 19:39, 11 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:CODOX-M/IVAC Regimen; Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen; McGrath Regimen
Overview
CODOX-M/IVAC regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) alternating with ifosfamide, etoposide and high-dose cytarabine (IVAC), used as a treatment for aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment for AIDS-related and high-risk Burkitt's lymphoma. Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.[1]
Regimen
CCyclophosphamide
VVincristine
DOXDoxorubicin
MMethotrexate
IIfosfamide
VVepesid (etoposide)
ACAra-C (cytarabine)
Indications
- AIDS-related and high-risk Burkitt's lymphoma[2]